Biostage Stock Price, News & Analysis (OTCMKTS:BSTGD)

$2.70 0.10 (3.85 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$2.70
Today's Range$2.40 - $2.87
52-Week Range$0.60 - $17.42
Volume18,342 shs
Average Volume22,716 shs
Market Capitalization$6.52 million
P/E Ratio-0.22
Dividend YieldN/A

About Biostage (OTCMKTS:BSTGD)

Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient's own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.

Receive BSTGD News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTGD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution


Debt-to-Equity RatioN/A
Current Ratio0.81%
Quick Ratio0.81%


Trailing P/E Ratio-0.217741759885678
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$80,000.00
Price / Sales84.71
Cash FlowN/A
Price / CashN/A
Book Value$2.07 per share
Price / Book1.30


Trailing EPS($12.40)
Net Income$-11,570,000.00
Net MarginsN/A
Return on Equity-1,113.18%
Return on Assets-284.79%


Outstanding Shares2,510,000

Biostage (OTCMKTS:BSTGD) Frequently Asked Questions

What is Biostage's stock symbol?

Biostage trades on the OTCMKTS under the ticker symbol "BSTGD."

How were Biostage's earnings last quarter?

Biostage Inc (OTCMKTS:BSTGD) posted its earnings results on Thursday, May, 11th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.09. View Biostage's Earnings History.

Who are some of Biostage's key competitors?

Who are Biostage's key executives?

Biostage's management team includes the folowing people:

  • John F. Kennedy, Chairman of the Board (Age 66)
  • James J. McGorry, Chief Executive Officer, Director (Age 59)
  • Thomas McNaughton Jr., Chief Financial Officer (Age 54)
  • Harout DerSimonian, Chief Scientific Officer
  • David M. Green, Director (Age 50)
  • Blaine H Mckee Ph.D., Director
  • John J. Canepa, Independent Director (Age 59)
  • Thomas H. Robinson, Independent Director (Age 58)

How do I buy Biostage stock?

Shares of Biostage can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biostage's stock price today?

One share of Biostage stock can currently be purchased for approximately $2.70.

How big of a company is Biostage?

Biostage has a market capitalization of $6.52 million and generates $80,000.00 in revenue each year. The biotechnology company earns $-11,570,000.00 in net income (profit) each year or ($12.40) on an earnings per share basis. Biostage employs 28 workers across the globe.

How can I contact Biostage?

Biostage's mailing address is 84 October Hill Road Suite 11, Holliston MA, 01746. The biotechnology company can be reached via phone at 774-233-7300 or via email at [email protected]

MarketBeat Community Rating for Biostage (BSTGD)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  75 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  129
MarketBeat's community ratings are surveys of what our community members think about Biostage and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biostage (OTCMKTS:BSTGD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$3.00
Price Target Upside: N/AN/AN/A745.79% upside

Biostage (OTCMKTS:BSTGD) Consensus Price Target History

Price Target History for Biostage (OTCMKTS:BSTGD)

Biostage (OTCMKTS:BSTGD) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
8/14/2017Maxim GroupReiterated RatingHoldView Rating Details
(Data available from 1/20/2016 forward)


Biostage (OTCMKTS:BSTGD) Earnings History and Estimates Chart

Earnings by Quarter for Biostage (OTCMKTS:BSTGD)

Biostage (OTCMKTS BSTGD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.07)($0.10)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.23)($0.14)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.21)($0.20)$0.03 millionViewListenView Earnings Details
11/10/2016Q316($0.25)($0.18)$26.00 millionViewN/AView Earnings Details
8/11/2016Q216($0.21)($0.17)$48.00 million$0.03 millionViewListenView Earnings Details
5/12/2016Q1($0.23)($0.18)ViewListenView Earnings Details
3/17/2016Q415($0.17)$1.60 million$0.01 millionViewListenView Earnings Details
11/12/2015Q315($0.19)$37.00 millionViewN/AView Earnings Details
8/13/2015Q215($0.44)$23.00 million$73.00 millionViewN/AView Earnings Details
3/19/2015Q4 2014($0.27)($0.36)$0.05 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.33)($0.34)ViewN/AView Earnings Details
8/8/2014Q214($0.27)($0.32)$0.02 millionViewN/AView Earnings Details
5/8/2014Q114($0.33)($0.39)$0.10 million$0.02 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Biostage (OTCMKTS:BSTGD) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Biostage (OTCMKTS:BSTGD)

No dividend announcements for this company have been tracked by

Insider Trades

Biostage (OTCMKTS BSTGD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.30%
Insider Trades by Quarter for Biostage (OTCMKTS:BSTGD)

Biostage (OTCMKTS BSTGD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2017Saverio LafrancescaInsiderBuy100,000$0.37$37,000.00293,998View SEC Filing  
8/23/2017Saverio LafrancescaInsiderBuy150,000$0.32$48,000.00193,998View SEC Filing  
10/12/2016Harout DersimonianInsiderBuy10,000$0.91$9,100.0010,000View SEC Filing  
8/26/2016John F KennedyDirectorBuy16,182$0.93$15,049.2658,406View SEC Filing  
8/25/2016James Joseph McgorryInsiderBuy25,000$0.96$24,000.00126,300View SEC Filing  
6/21/2016James Joseph McgorryCEOBuy20,000$1.07$21,400.00101,300View SEC Filing  
6/13/2016Thomas H RobinsonDirectorBuy32,000$1.17$37,440.0050,000View SEC Filing  
5/25/2016John J CanepaDirectorBuy17,241$1.46$25,171.8617,241View SEC Filing  
5/20/2016James Joseph McgorryCEOBuy10,000$1.56$15,600.0081,300View SEC Filing  
5/20/2016John F KennedyDirectorBuy6,500$1.56$10,140.0042,224View SEC Filing  
5/20/2016Thomas McnaughtonCFOBuy5,000$1.56$7,800.00203,628View SEC Filing  
5/19/2016Thomas H RobinsonDirectorBuy18,000$1.36$24,480.0018,000View SEC Filing  
12/17/2015Saverio LafrancescainsiderSell2,393$1.93$4,618.4943,998View SEC Filing  
12/1/2015John F KennedyDirectorBuy9,000$2.95$26,550.0035,724View SEC Filing  
12/1/2015Saverio LafrancescaInsiderBuy10,000$3.01$30,100.0043,998View SEC Filing  
11/19/2015James Joseph McgorryCEOBuy10,000$1.79$17,900.0071,300View SEC Filing  
11/18/2015Thomas McnaughtonCFOBuy10,000$1.56$15,600.00191,128View SEC Filing  
11/17/2015David GreenDirectorBuy25,000$1.34$33,500.00313,259View SEC Filing  
11/17/2015Thomas McnaughtonCFOBuy15,000$1.32$19,800.00181,128View SEC Filing  
9/18/2015Saverio LafrancescainsiderBuy9,500$1.29$12,255.0033,998View SEC Filing  
8/28/2015Saverio LafrancescaInsiderBuy2,500$0.96$2,400.0014,214View SEC Filing  
8/26/2015Thomas McnaughtonCFOBuy10,000$0.88$8,800.00166,128View SEC Filing  
8/24/2015John F KennedyDirectorBuy12,000$0.83$9,960.0026,724View SEC Filing  
8/21/2015James Joseph McgorryCEOBuy31,300$0.74$23,162.0061,300View SEC Filing  
8/21/2015Thomas McnaughtonCFOBuy100,000$0.66$66,000.00156,128View SEC Filing  
6/4/2015John F KennedyDirectorBuy1,000$2.13$2,130.00View SEC Filing  
6/3/2015John F KennedyDirectorBuy1,000$1.95$1,950.00View SEC Filing  
6/3/2015Thomas McnaughtonCEOBuy16,000$1.85$29,600.00View SEC Filing  
6/2/2015David GreenDirectorBuy26,600$1.81$48,146.00View SEC Filing  
6/2/2015Thomas McnaughtonCEOBuy8,000$1.80$14,400.00View SEC Filing  
6/1/2015John F KennedyDirectorBuy10,000$1.67$16,700.00View SEC Filing  
6/1/2015Thomas McnaughtonCEOBuy3,000$1.74$5,220.00View SEC Filing  
5/29/2015Thomas McnaughtonCEOBuy5,000$1.91$9,550.00View SEC Filing  
2/18/2015David GreenCEOBuy50,000$1.75$87,500.00View SEC Filing  
2/13/2015Thomas McnaughtonCFOBuy14,000$2.67$37,380.00View SEC Filing  
(Data available from 1/1/2013 forward)


Biostage (OTCMKTS BSTGD) News Headlines

No headlines for this company have been tracked by

SEC Filings

Biostage (OTCMKTS:BSTGD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Biostage (OTCMKTS:BSTGD) Income Statement, Balance Sheet and Cash Flow Statement


Biostage (OTCMKTS BSTGD) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.